POINT-Logo-Colour (blue).png
POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress
October 17, 2022 08:30 ET | POINT Biopharma
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA...
POINT-Logo-Colour (blue).png
POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET | POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
August 08, 2022 08:30 ET | POINT Biopharma
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at...
POINT-Logo-Colour (1).png
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
May 05, 2022 09:15 ET | POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT-Logo-Colour (1).png
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
April 26, 2022 08:30 ET | POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
POINT-Logo-Colour (1).png
POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting
April 11, 2022 16:30 ET | POINT Biopharma
POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...
Nextnav logo.png
NextNav Showcases APNT Backup to GNSS at European Commission's Joint Research Centre’s Trial
February 01, 2022 13:36 ET | NextNav
SUNNYVALE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NextNav (Nasdaq: NN) today announced that it has recently participated in the European Commission’s Joint Research Centre (JRC) alternative...
logo-nextnav-alt-landscape-blue-gradiated.png
NextNav and Satelles Collaborate to Establish an Alternative PNT Testbed in the San Francisco Bay Area
October 05, 2021 09:00 ET | NextNav; Satelles, Inc.
SUNNYVALE, Calif. and RESTON, Va., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NextNav and Satelles, Inc. today announced that they have partnered on an alternative positioning, navigation, and timing (PNT)...
Point.JPG
POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor
September 28, 2021 08:00 ET | POINT Biopharma
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic...
Point.JPG
POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC
September 23, 2021 08:00 ET | POINT Biopharma
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS,...